{"id":905141,"date":"2025-11-04T13:12:45","date_gmt":"2025-11-04T18:12:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\/"},"modified":"2025-11-04T13:12:45","modified_gmt":"2025-11-04T18:12:45","slug":"sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\/","title":{"rendered":"SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">MIAMI, Nov.  04, 2025  (GLOBE NEWSWIRE) &#8212; SAb Biotherapeutics, Inc. (Nasdaq: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=tYQa49e6EaIUQakpbY2zFFOIbeoBHYhlgr_b83bVJ4WCnyfD-v3n1FIsVg0Ne5Nl920gscc0G4LuVa3gg-Z_kfHOFY0mmEJYlRiCEdkKriacm14UOtEmdkwBfjKLAHvT\" rel=\"nofollow\" target=\"_blank\">SABS<\/a>), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced\u00a0that four oral presentations and two poster presentations have been accepted for presentation at the 51st Annual Conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD) being held November 5-8, 2025 in Montr\u00e9al, Canada. Data highlights the progress of SAB BIO\u2019s lead program, SAB-142, which is in development for delaying the progression of T1D in new onset Stage 3 patients.<\/p>\n<p>Key data to be presented includes:<\/p>\n<ul type=\"disc\">\n<li>Data from the Phase 1 study showcasing the clinically validated, multi-specific mechanism of action with sustained immunomodulation of SAB-142.<\/li>\n<li>Safety data from the Phase 1 trial of SAB-142 demonstrating a favorable safety profile, characterized as not causing serum sickness or anti-drug antibodies at target dose.<\/li>\n<li>Details of the novel pharmacokinetic assay for measuring SAB-142.<\/li>\n<\/ul>\n<p>\u201cWe are making significant progress with the development of SAB-142, and the data we are sharing at this year\u2019s ISPAD annual conference adds to the supporting body of evidence for SAB-142 as a potential best-in-class therapy for the treatment of Stage 3 autoimmune type 1 diabetes,\u201d said presenting author Christoph Bausch, Chief Operating Officer, SAB BIO.<\/p>\n<p>\n        <strong>Oral Presentation Details: <\/strong><br \/>\n        <br \/>\n        <strong>Title: <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=_XuWF8Nx8lutJxmMgPNrKRw1y0Ezw4jhnzW_14OePhB8Pf6qa6i929SjGU12PGfe8a2809Yeqy-czrG7261xzdKxdwZK_6X1DppnFbTQbdzhNAiQtKsT4zfehTNqBrmss9HDu_gxsNDnCeSSsXc14h3-uegrUwkAPjIgh9RN5UzD9-rGippZ4tR8yNmoJf63vfxxxEGCH2-Hf83_Mi-y5dw8edSoIlt9Ede8dX5WKxw6DKAz__qyDbw0ZrfIPA_tyigdt0Kv6L9VajwGL4JvILp46jqg7O-T5iqJ28XCri4=\" rel=\"nofollow\" target=\"_blank\">Specimen quality for multicenter clinical trials: comparing novel blood preservation methods to cryopreserved PBMC<\/a><br \/>\n        <br \/>\n        <strong>Session: <\/strong>Oral Session II: Genes, cells and pathways | Presentation 12<br \/><strong>Presenter:<\/strong> Eric Sandhurst, PhD, Director, Program Management, SAB BIO<br \/><strong>Presentation Date &amp; Time:<\/strong> Wednesday, November 5, 2025 | 4:38 \u2013 4:46 p.m. ET <br \/><strong>Location:<\/strong> Session Hall 3<\/p>\n<p>\n        <strong>Title: <\/strong>Profiling the Binding Specificities of SAB-142, a Fully Human Anti-Thymocyte Globulin, Against T Cell Surface Proteins<br \/><strong>Session:<\/strong> Oral Session V: Treatment in diabetes | Presentation 42<br \/><strong>Presenter:<\/strong> Diane Maher, PhD, Director, Program Management, SAB BIO<br \/><strong>Presentation Date &amp; Time: <\/strong>Friday, November 7, 2025 | 11:38 \u2013 11:46 p.m. ET <br \/><strong>Location:<\/strong> Session Hall 3<\/p>\n<p>\n        <strong>Title: <\/strong>Immunomodulation Without Sustained Lymphodepletion: SAB-142, a Fully Human Anti-Thymocyte Globulin<br \/><strong>Session:<\/strong> Oral Session V: Treatment in diabetes | Presentation 43<br \/><strong>Presenter:<\/strong>\u00a0Stan Stoyanov, MD, Vice President, Clinical Development, SAB BIO<br \/><strong>Presentation Date &amp; Time:<\/strong> Friday, November 7, 2025 | 11:46 \u2013 11:54 p.m. ET <br \/><strong>Location: <\/strong>Session Hall 3<\/p>\n<p>\n        <strong>Title: <\/strong>Mechanism of Action of a Fully Human Anti-Thymocyte Globulin, SAB-142, for the Treatment of Type 1 Diabetes<br \/><strong>Session:<\/strong> Oral Session V: Treatment in diabetes | Presentation 44<br \/><strong>Presenter:<\/strong> Christoph Bausch, PhD, Chief Operating Officer, SAB BIO<br \/><strong>Presentation Date &amp; Time: <\/strong>Friday, November 7, 2025 | 11:54 a.m. \u2013 12:02 p.m. ET <br \/><strong>Location:<\/strong> Session Hall 3<\/p>\n<p>\n        <strong>Poster Presentation Details: <\/strong><br \/>\n        <br \/>\n        <strong>Title: <\/strong><br \/>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3l_tuCVz3ZEs3qnQhp1qLOEBOvvNW4AASLMbFbXEeXqMMn621iQZpvfmrRiYheAJ5UEGZcxRYiIqmxACohPuk8q56vwCkKtblbQePD3krmYvOKtvD2GT6fhKEK20q0axzgShY6pv5BlLo8XTkMBJLxWjttWyRC65t2IphrGydEdBGOakLjnlRgX1dl0vo3r23VnGyHdwrBS3Ct-XpbYnuADnDQJWrFcTkqzOOj3iEnhFd71_71eEkjx6ry4rMcPS\" rel=\"nofollow\" target=\"_blank\">Novel Pharmacokinetic (PK) Assay for Measuring SAB-142, a Fully Human Anti-Thymocyte Globulin<\/a><br \/>\n        <br \/>\n        <strong>Session: <\/strong>Poster Corner 4: Novel Advances and Interventions; Diabetes in Developing Countries and Migrant Populations\u00a0| Presentation 123<br \/><strong>Presenter: <\/strong> Evan Gardner, Senior Manager, Clinical Bioanalysis, SAB BIO<br \/><strong>Presentation Date &amp; Time: <\/strong> Thursday, November 6, 2025 | 3:15 \u2013 4:15 p.m. ET<br \/><strong>Location: <\/strong>Exhibition &amp; Poster Area<\/p>\n<p>\n        <strong>Title: <\/strong>Safety Profile of SAB-142: a Fully Human Anti-Thymocyte Globulin<br \/><strong>Session: <\/strong>Poster Corner 2: New insulins; Adjunctive Therapies; Other Pharmacologic Agents; Novel Advances and Interventions<br \/><strong>Presenter:<\/strong> Stan Stoyanov, MD, Vice President, Clinical Development, SAB BIO<br \/><strong>Presentation Date &amp; Time: <\/strong>Friday, November 7, 2025 | 3:15 \u2013 4:15 p.m. ET<br \/><strong>Location: <\/strong>Exhibition &amp; Poster Area<\/p>\n<p>\n        <strong>About SAB-142<\/strong><br \/>\n        <br \/>SAB-142 is a potentially disease-modifying, re-dosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes (T1D). SAB-142 is a multi-specific, fully human anti-thymocyte globulin (hATG) with a mechanism of action analogous to that of rabbit ATG (rATG). rATG has demonstrated in multiple clinical trials the ability to slow disease progression in patients with new or recent onset of Stage 3 T1D. SAB-142, like rATG, directly targets multiple immune cells involved in destroying pancreatic beta cells, including modulation of \u201cbad acting\u201d T-lymphocytes like Cytotoxic T-cells. By stopping immune cells from attacking beta cells, this treatment has the potential to preserve insulin-producing beta cells.<\/p>\n<p>\n        <strong>About SAB BIO<\/strong><br \/>\n        <br \/>SAB BIO is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The Company\u2019s lead asset, SAB-142, targets autoimmune T1D with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. Using advanced genetic engineering and antibody science, SAB BIO developed a proprietary platform which holds the potential to generate additional novel therapeutic candidates utilizing the human immune response, without the need for human donors or convalescent plasma. SAB BIO has optimized genetic engineering in the development of transchromosomic cattle, or Tc Bovine, to produce hIgG. SAB BIO\u2019s drug development production system is able to generate a diverse repertoire of specifically targeted, high-potency, hIgGs that can address a wide range of serious unmet needs in human diseases. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=C_l0UCBrAReUzjYOIJdGRP4sgxbDrfM5UrT2bEJXqN4PEpvGWCGwKWoBISr77ImyQ0bTtBVXyoNOHgnK9PCR7w==\" rel=\"nofollow\" target=\"_blank\">www.sab.bio<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>Certain statements made in this current report that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as \u201cbelieve,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cto be,\u201d \u201cestimate,\u201d \u201ccontinue,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cexpect,\u201d \u201cshould,\u201d \u201cwould,\u201d \u201cplan,\u201d \u201cpredict,\u201d \u201cpotential,\u201d \u201cseem,\u201d \u201cseek,\u201d \u201cfuture,\u201d \u201coutlook,\u201d and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding future events, including statements about the development and clinical trial results of the Company\u2019s T1D program and other discovery programs.<\/p>\n<p>These statements are based on the current expectations of SAB BIO and are not predictions of actual performance, and are not intended to serve as, and must not be relied on, by any investor as a guarantee, prediction, definitive statement, or an assurance, of fact or probability. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties and other factors which may be beyond our control. Actual events and circumstances are difficult or impossible to predict, and these risks and uncertainties may cause our or our industry\u2019s results, performance, or achievements to be materially different from those anticipated by these forward-looking statements. A further description of risks and uncertainties can be found in the sections captioned \u201cRisk Factors\u201d in our most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q, as may be amended or supplemented from time to time, and other filings with or submissions to, the U.S. Securities and Exchange Commission, which are available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MgoIVrLgtelUYlleSKOaQkk7xjiJtXB-A17wZY9eKIIong-9yQgRVZekDmHt8RSVhfb3tZV4caRuM6pRdgjaIc4CBOsPcV1h2lDWtTAU2ARxIKZE9Uvgt6-ObrV9nc7As2J_8VkesEFePik7xE2RzVOvJffwR58s4F1NCqUxFPFNLw2i9UNwC_y4SxUqs5wKv98B1JbyOBGxInpKguJh1DPKv3NKibXBnjnPLRmZERXrFnkxwkbj9wzuyww7qjtmSfZ86LYQzBY74B_cLBq-7A==\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.sec.gov\/.<\/a> Except as otherwise required by law, SAB BIO disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events, or circumstances or otherwise.<\/p>\n<p>\n        <strong>CONTACTS<\/strong>\n      <\/p>\n<p>\n        <strong>Investor Relations:<\/strong><br \/>\n        <br \/>Cristi Barnett<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=x66xYsXMrGJMyBHiQyrPVnQqyIIT82qBynvbHV_0zaXEf0-DMnrlnHwMA_PhM0TrZ1zVnpwUWQMim5gScGo5Hw==\" rel=\"nofollow\" target=\"_blank\">ir@sab.bio<\/a><\/p>\n<p>\n        <strong>Media:<\/strong><br \/>\n        <br \/>Sheila Carlson<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IByBDW6kf5al5rCPlUOS1rjehFbu0o07M1lHeXheYQdrlgkQ8DdJOOkoww7vxPNQiL1Xul-uryVv5rjaCHT58g==\" rel=\"nofollow\" target=\"_blank\">media@sab.bio<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Nzg2NCM3MjQxNzU3IzIyMjE3NDE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/YWNmYjIwNjMtMGFlNC00YjZjLTg5NzMtNWQ0NWUwZmNjYjdjLTEyMzMyOTQtMjAyNS0xMS0wNC1lbg==\/tiny\/SAB-Biotherapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) &#8212; SAb Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced\u00a0that four oral presentations and two poster presentations have been accepted for presentation at the 51st Annual Conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD) being held November 5-8, 2025 in Montr\u00e9al, Canada. Data highlights the progress of SAB BIO\u2019s lead program, SAB-142, which is in development for delaying the progression of T1D in new onset Stage 3 patients. Key data to be presented includes: Data from the Phase 1 study showcasing the clinically validated, multi-specific mechanism of action with sustained immunomodulation of SAB-142. Safety data &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-905141","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) &#8212; SAb Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced\u00a0that four oral presentations and two poster presentations have been accepted for presentation at the 51st Annual Conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD) being held November 5-8, 2025 in Montr\u00e9al, Canada. Data highlights the progress of SAB BIO\u2019s lead program, SAB-142, which is in development for delaying the progression of T1D in new onset Stage 3 patients. Key data to be presented includes: Data from the Phase 1 study showcasing the clinically validated, multi-specific mechanism of action with sustained immunomodulation of SAB-142. Safety data &hellip; Continue reading &quot;SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-04T18:12:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Nzg2NCM3MjQxNzU3IzIyMjE3NDE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142\",\"datePublished\":\"2025-11-04T18:12:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\\\/\"},\"wordCount\":1121,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2Nzg2NCM3MjQxNzU3IzIyMjE3NDE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\\\/\",\"name\":\"SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2Nzg2NCM3MjQxNzU3IzIyMjE3NDE=\",\"datePublished\":\"2025-11-04T18:12:45+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2Nzg2NCM3MjQxNzU3IzIyMjE3NDE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2Nzg2NCM3MjQxNzU3IzIyMjE3NDE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\/","og_locale":"en_US","og_type":"article","og_title":"SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142 - Market Newsdesk","og_description":"MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) &#8212; SAb Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced\u00a0that four oral presentations and two poster presentations have been accepted for presentation at the 51st Annual Conference of the International Society for Pediatric and Adolescent Diabetes (ISPAD) being held November 5-8, 2025 in Montr\u00e9al, Canada. Data highlights the progress of SAB BIO\u2019s lead program, SAB-142, which is in development for delaying the progression of T1D in new onset Stage 3 patients. Key data to be presented includes: Data from the Phase 1 study showcasing the clinically validated, multi-specific mechanism of action with sustained immunomodulation of SAB-142. Safety data &hellip; Continue reading \"SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-04T18:12:45+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Nzg2NCM3MjQxNzU3IzIyMjE3NDE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142","datePublished":"2025-11-04T18:12:45+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\/"},"wordCount":1121,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Nzg2NCM3MjQxNzU3IzIyMjE3NDE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\/","name":"SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Nzg2NCM3MjQxNzU3IzIyMjE3NDE=","datePublished":"2025-11-04T18:12:45+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Nzg2NCM3MjQxNzU3IzIyMjE3NDE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2Nzg2NCM3MjQxNzU3IzIyMjE3NDE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/sab-bio-to-present-data-at-the-international-society-for-pediatric-and-adolescent-diabetes-annual-conference-showcasing-progress-in-the-development-of-sab-142\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SAB BIO to Present Data at the International Society for Pediatric and Adolescent Diabetes Annual Conference Showcasing Progress in the Development of SAB-142"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/905141","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=905141"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/905141\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=905141"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=905141"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=905141"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}